Antitumour Activity Of Pulmbagin Against Dalton's Ascitic Lymphoma
The antitumour activity of plumbagin (2-methyl 5-hydroxy, 1,4 napthoquinone) has been evaluated against Dalton's ascitic lymphoma (DAL) in Swiss albino mice. A significant enhancement of mean survival time of Plumbagin treated tumour bearing mice was found with respect to control group. Plumbagin treatment was found to enhance peritoneal cell counts. When these Plumbagin treated animals underwent I. p. inoculation with DAL cells, tumour cell growth was found to be inhibited. At 14 days after transplantation, Plumbagin treated groups were able to reverse the changes in the haemotological parameters, protein and PCV consequent to tumour inoculation.